Our Development Pipeline We are a leader in cannabinoid-based combination therapy with a portfolio of seven patents filed with the United States Patent and Trademark Office (“USPTO”), for indications of Alzheimer’s, Parkinson’s, pain, seizures, and eating disorders. Our most advanced formulation for indications of Alzheimer’s will be available to patients in early 2018.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.